Lineage Cell Therapeutics, Inc.
LCTX
$0.4899
-$0.0101-2.02%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.27M | -3.03M | -5.76M | -6.54M | -4.78M |
| Total Depreciation and Amortization | 151.00K | 141.00K | 142.00K | 175.00K | 175.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -207.00K | 818.00K | 1.55M | 1.51M | -192.00K |
| Change in Net Operating Assets | -3.02M | -3.71M | -1.11M | -929.00K | -1.23M |
| Cash from Operations | -6.35M | -5.79M | -5.18M | -5.78M | -6.02M |
| Capital Expenditure | -365.00K | -112.00K | -50.00K | -38.00K | -91.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.00M | 4.00M | -8.74M | -- | 9.83M |
| Cash from Investing | 2.64M | 3.89M | -8.79M | -38.00K | 9.74M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -14.00K | -13.00K | -14.00K | -13.00K | -13.00K |
| Issuance of Common Stock | 21.81M | 10.00K | 120.00K | 14.17M | -- |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -23.00K | -199.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -58.00K | 0.00 | -1.00K | -112.00K | 199.00K |
| Cash from Financing | 21.73M | -3.00K | 105.00K | 14.02M | -13.00K |
| Foreign Exchange rate Adjustments | 25.00K | 38.00K | -88.00K | -70.00K | 282.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.05M | -1.86M | -13.95M | 8.13M | 3.99M |
